Selenium modulates 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) biosynthesis in bovine aortic endothelial cells

Antioxid Redox Signal. 2001 Dec;3(6):1147-52. doi: 10.1089/152308601317203657.

Abstract

Selenium (Se) deficiency has been reported to increase platelet-activating factor (PAF) production in human endothelial cells; however, the mechanism is unclear. This study demonstrated that tumor necrosis factor-alpha (TNF-alpha) stimulated Se-deficient bovine aortic endothelial cells (BAEC) produced significantly more PAF than Se-supplemented cells. Moreover, the increase in the level of PAF was associated with enhanced activity of two anabolic enzymes in the remodeling pathway: phospholipase A2 and Lyso-PAF:acetyl-coenzyme A acetyltransferase (Lyso-PAF-AcT). In contrast, the activity of the PAF catabolic enzyme, PAF-acetylhydrolase, was not affected by Se status. Interestingly, prostacyclin, a potent vasodilator and inhibitor of platelet aggregation, inhibited the activity of Lyso-PAF-AcT and reduced the PAF production in TNF-alpha-stimulated BAEC. Therefore, we conclude that Se deficiency alters PAF production in TNF-alpha-stimulated BAEC by altering the activity of anabolic enzymes involved in the remodeling pathway partially through the inhibition of prostacyclin production.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antioxidants / pharmacology*
  • Aorta / cytology
  • Cattle
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / cytology
  • Epoprostenol / pharmacology
  • Platelet Activating Factor / biosynthesis*
  • Platelet Aggregation
  • Reactive Oxygen Species
  • Selenium / metabolism
  • Selenium / pharmacology*
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Antioxidants
  • Platelet Activating Factor
  • Reactive Oxygen Species
  • Tumor Necrosis Factor-alpha
  • Epoprostenol
  • Selenium